共 6 条
[4]
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
[J].
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE,
2015, 107 (12)